ALT5 Sigma (ALTS) Competitors $3.87 -0.62 (-13.81%) Closing price 04:00 PM EasternExtended Trading$4.02 +0.15 (+3.85%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALTS vs. TERN, MAZE, TRML, XNCR, ANAB, PVLA, ARVN, SAGE, ORKA, and SVRAShould you be buying ALT5 Sigma stock or one of its competitors? The main competitors of ALT5 Sigma include Terns Pharmaceuticals (TERN), Maze Therapeutics (MAZE), Tourmaline Bio (TRML), Xencor (XNCR), AnaptysBio (ANAB), Palvella Therapeutics (PVLA), Arvinas (ARVN), Sage Therapeutics (SAGE), Oruka Therapeutics (ORKA), and Savara (SVRA). These companies are all part of the "pharmaceutical products" industry. ALT5 Sigma vs. Its Competitors Terns Pharmaceuticals Maze Therapeutics Tourmaline Bio Xencor AnaptysBio Palvella Therapeutics Arvinas Sage Therapeutics Oruka Therapeutics Savara Terns Pharmaceuticals (NASDAQ:TERN) and ALT5 Sigma (NASDAQ:ALTS) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk. Do institutionals and insiders have more ownership in TERN or ALTS? 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 1.5% of Terns Pharmaceuticals shares are owned by insiders. Comparatively, 4.9% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate TERN or ALTS? Terns Pharmaceuticals currently has a consensus price target of $15.61, suggesting a potential upside of 121.10%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Terns Pharmaceuticals is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TERN or ALTS more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to ALT5 Sigma's net margin of -74.89%. Terns Pharmaceuticals' return on equity of -27.35% beat ALT5 Sigma's return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -27.35% -26.18% ALT5 Sigma -74.89%-179.27%-16.28% Does the media prefer TERN or ALTS? In the previous week, Terns Pharmaceuticals had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 9 mentions for Terns Pharmaceuticals and 8 mentions for ALT5 Sigma. Terns Pharmaceuticals' average media sentiment score of 1.49 beat ALT5 Sigma's score of 0.08 indicating that Terns Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALT5 Sigma 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, TERN or ALTS? Terns Pharmaceuticals has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Which has stronger earnings and valuation, TERN or ALTS? ALT5 Sigma has higher revenue and earnings than Terns Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$88.85M-$1.04-6.79ALT5 Sigma$12.53M6.67-$6.24MN/AN/A SummaryTerns Pharmaceuticals beats ALT5 Sigma on 8 of the 13 factors compared between the two stocks. Get ALT5 Sigma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricALT5 SigmaFIN IndustryFinance SectorNASDAQ ExchangeMarket Cap$97.03M$7.80B$12.53B$9.91BDividend YieldN/A4.65%5.43%4.49%P/E RatioN/A17.14230.0626.65Price / Sales6.676.7031.08163.66Price / CashN/A25.5819.0628.92Price / Book7.904.682.346.52Net Income-$6.24M$313.53M$1.01B$266.21M7 Day Performance-53.65%-3.16%0.11%-0.76%1 Month Performance-43.17%0.55%3.71%3.83%1 Year Performance76.71%32.26%542.65%24.39% ALT5 Sigma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSALT5 Sigma0.3924 of 5 stars$3.87-13.8%N/A+93.5%$97.03M$12.53M0.00170Options VolumeGap DownTERNTerns Pharmaceuticals3.9614 of 5 stars$7.25+8.4%$15.63+115.5%+2.9%$585.45MN/A-6.9740News CoveragePositive NewsAnalyst ForecastMAZEMaze TherapeuticsN/A$14.05+5.6%$25.60+82.2%N/A$583.66M$167.50M0.00121News CoveragePositive NewsAnalyst ForecastHigh Trading VolumeTRMLTourmaline Bio2.4166 of 5 stars$23.50+3.6%$50.14+113.4%+56.2%$582.70MN/A-6.8544Positive NewsXNCRXencor3.8077 of 5 stars$7.90-1.4%$23.71+200.2%-50.8%$571.30M$110.49M-3.29280News CoverageAnalyst ForecastANABAnaptysBio2.4406 of 5 stars$19.96-0.7%$46.13+131.1%-37.6%$562.74M$91.28M-4.46100News CoveragePositive NewsPVLAPalvella Therapeutics1.8464 of 5 stars$53.76+7.2%$58.50+8.8%N/A$554.42M$42.81M-4.44N/ANews CoverageARVNArvinas2.8115 of 5 stars$7.54+0.8%$19.76+162.1%-69.0%$549.16M$263.40M-7.47420News CoveragePositive NewsSAGESage Therapeutics1.492 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690ORKAOruka Therapeutics2.988 of 5 stars$14.81+2.1%$40.38+172.6%N/A$543.41MN/A-5.27N/ANews CoveragePositive NewsSVRASavara3.1949 of 5 stars$3.31+5.4%$6.17+86.3%-18.8%$542.71MN/A-6.6220News CoveragePositive NewsAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies TERN Alternatives MAZE Alternatives TRML Alternatives XNCR Alternatives ANAB Alternatives PVLA Alternatives ARVN Alternatives SAGE Alternatives ORKA Alternatives SVRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALTS) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALT5 Sigma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ALT5 Sigma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
